Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer. Read More ›

The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile. Read More ›

Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support. Read More ›

Accurate anatomic subtyping, optimal diagnostic imaging, and molecular classification are among the most pressing needs with NETs. Read More ›

The future of PRRT lies in its use in combination therapies, including PRRT with chemotherapy, immunotherapy, and as neoadjuvant/adjuvant therapy with surgery. Read More ›

Targeted alpha-particle therapy is in development for targeted radionuclide therapy of NETs, employing alpha decay to treat diseased tissue at close proximity. Read More ›

Telotristat ethyl is safe and effective in reducing intractable diarrhea in patients with carcinoid syndrome. Read More ›

An expert working group developed specific ideas for future research programs in NETs, as well as ways to improve access to NET clinical trials. Read More ›

The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP). Read More ›

The current post-hoc subanalysis of a phase 4 open-label study concluded that the effects on platelet counts after eltrombopag treatment for >2 years was comparable between the persistent immune thrombocytopenia (ITP) and the chronic ITP cohorts, with similar safety profiles. Read More ›